Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7697321 | 0.84 | MAOA (0.51) | SIGMAR1COMTACHE | |
| SCHEMBL19116976 | 0.83 | SIGMAR1 (0.50) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL325929 | 0.83 | SIGMAR1 (0.48) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL15241752 | 0.77 | ALDH1A1 (0.53) | SIGMAR1DRD4POLB | |
| SCHEMBL2904840 | 0.76 | SIGMAR1 (0.53) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL12612421 | 0.75 | SIGMAR1 (0.48) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL11136071 | 0.75 | SLC6A1 (0.57) | SIGMAR1LMNA | |
| SCHEMBL10640414 | 0.75 | SIGMAR1 (0.52) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL325460 | 0.73 | SIGMAR1 (0.50) | SIGMAR1MC4RDRD4 | |
| SCHEMBL10914396 | 0.73 | CYP2D6 (0.47) | SIGMAR1MC4RLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| CN-106458912-B | Bicyclic fused heteroaryl or aryl compounds and their use as IRAK4 mimetics | 辉瑞公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3536685-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | Pfizer Inc (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190270751-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10329302-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-6635661-B2 | Piperidinyl amide compounds | SEPRACOR INC. | 2003-10-21 | — | — | US | disclosed |
| WO-2002069895-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1187810-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020016339-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | KLEIN SCOTT I (US) | 2002-02-07 | — | — | US | disclosed |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. | 2002-02-07 | — | — | US | disclosed |
| US-6277865-B1 | ANTICOAGULANTS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-08-21 | — | — | US | disclosed |
| EP-1080075-A4 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1080075-A1 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000071518-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-1999048870-A1 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270751-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | SIGMAR1 3079/4885MC4R 893/4885COMT 202/4885 |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | SIGMAR1 3079/4885MC4R 893/4885COMT 202/4885 |
| US-20020016339-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | F11, F5, TFPI | SIGMAR1 2061/4885MC4R 3217/4885COMT 3628/4885 |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | SIGMAR1 3079/4885MC4R 893/4885COMT 202/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | SIGMAR1 3303/4885MC4R 479/4885COMT 92/4885 |
| US-10329302-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | SIGMAR1 3079/4885MC4R 893/4885COMT 202/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | SIGMAR1 3303/4885MC4R 479/4885COMT 92/4885 |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | SIGMAR1 40/4885MC4R 408/4885COMT 1519/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | SIGMAR1 3079/4885MC4R 893/4885COMT 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.